AU2017258765A1 - Methods for the treatment of infection - Google Patents

Methods for the treatment of infection Download PDF

Info

Publication number
AU2017258765A1
AU2017258765A1 AU2017258765A AU2017258765A AU2017258765A1 AU 2017258765 A1 AU2017258765 A1 AU 2017258765A1 AU 2017258765 A AU2017258765 A AU 2017258765A AU 2017258765 A AU2017258765 A AU 2017258765A AU 2017258765 A1 AU2017258765 A1 AU 2017258765A1
Authority
AU
Australia
Prior art keywords
infection
subject
pharmaceutical composition
ajulemic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017258765A
Other languages
English (en)
Inventor
Tracey L. BONFIELD
Derek W. Gilroy
Madhur MOTWANI
Mark Tepper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of AU2017258765A1 publication Critical patent/AU2017258765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017258765A 2016-04-29 2017-04-28 Methods for the treatment of infection Abandoned AU2017258765A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329,514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400,503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470,419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (1)

Publication Number Publication Date
AU2017258765A1 true AU2017258765A1 (en) 2018-11-29

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017258765A Abandoned AU2017258765A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Country Status (7)

Country Link
US (2) US20190133995A1 (https=)
EP (1) EP3448377A4 (https=)
JP (1) JP2019515927A (https=)
CN (1) CN109715152A (https=)
AU (1) AU2017258765A1 (https=)
CA (1) CA3022391A1 (https=)
WO (1) WO2017190070A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368023A (zh) * 2018-06-14 2021-02-12 株式会社钟化 包含药物活性成分的制剂
US20230233456A1 (en) * 2021-03-25 2023-07-27 Per Os Biosciences, Llc Compositions and methods for treating coronavirus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
WO2009158499A2 (en) * 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
BR112015019180A8 (pt) * 2013-02-12 2018-01-30 Corbus Pharmaceuticals Inc ácidos tetrahidrocanabinol-11-óicos ultrapuros
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
US20190133995A1 (en) 2019-05-09
WO2017190070A1 (en) 2017-11-02
EP3448377A1 (en) 2019-03-06
EP3448377A4 (en) 2019-12-25
US20200405687A1 (en) 2020-12-31
CN109715152A (zh) 2019-05-03
JP2019515927A (ja) 2019-06-13
CA3022391A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
Mohr et al. Current options in antifungal pharmacotherapy
RU2760682C2 (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
ES2627268T3 (es) Aplicación de preparados de combinación que contienen antimicóticos
CN1688306A (zh) 泊沙康唑用于治疗真菌感染的用途
US20100209540A1 (en) Inhalation formulation for treating and prophylactic use in bacteria, mycobacterial and fungal respiratory infections
JP2020528928A (ja) ジピベフリンの使用方法
US12403169B2 (en) Compositions and methods related to Rhamnus prinoides (gesho) extract for the inhibition of polymicrobial biofilm formation
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
WO2016131100A1 (en) Methods of treating infectious diseases
US20200405687A1 (en) Methods for the treatment of infection
CN103957907B (zh) 抗真菌剂
EP2543370A1 (en) Compositions and Methods for Treating Herpes Simplex Virus
KR20010005624A (ko) 제약 조성물
US9446017B2 (en) Compositions and methods for treating herpes simplex virus
CN102949387B (zh) 用于治疗单纯疱疹病毒的组合物和方法
De Socio et al. AmBisome administration for Candida albicans shunt infections
JP2023548863A (ja) テトラヒドロカンナビノールおよびそれを含む組成物を用いて急性呼吸不全および/または急性呼吸窮迫症候群を治療するための組成物および方法
HK40008280A (en) Methods for the treatment of infection
US20230263812A1 (en) Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including Same
CA3077447A1 (en) Method to treat antimicrobial resistant candida
de Araujo et al. Decrease in Fungizone™ toxicity induced by the use of Lipofundin™ as a dilutent: an in vitro study
Lewis et al. Update on amphotericin B pharmacology and dosing for common systemic mycoses
Xu et al. Gastrodin alleviates angiotensin Ⅱ-induced hypertension and myocardial apoptosis and PRDX2/p53 pathway activation
WO2015134796A1 (en) Poloxamer and itraconazole effect on fungus/yeast
Graybill Chemotherapy of the systemic mycoses

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period